DR. GREGG J SILVERMAN, M.D.
Osteopathic Medicine at Gilman Dr, La Jolla, CA
License number
California G49612
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California G49612
Category
Osteopathic Medicine
Type
Rheumatology
Address
Address
9500 Gilman Dr, La Jolla, CA 92093
Phone
(858) 534-5439
(858) 822-5230 (Fax)
(858) 822-5230 (Fax)
Professional information
Dr. Gregg J Silverman, La Jolla CA - MD (Doctor of Medicine)
Specialties:
Rheumatology
Address:
Arthritis Center at UCSD
9350 Campus Point Dr STE B, La Jolla 92037
(858) 657-6110 (Phone)
9500 Gilman Dr, La Jolla 92093
(858) 534-5439 (Phone), (858) 822-5230 (Fax)
9350 Campus Point Dr STE B, La Jolla 92037
(858) 657-6110 (Phone)
9500 Gilman Dr, La Jolla 92093
(858) 534-5439 (Phone), (858) 822-5230 (Fax)
Conditions:
Arthritis, Dermatomyositis, Fibromyalgia, Polymyositis, Rheumatoid Arthritis
Languages:
English
Education:
Medical School
Rutgers Medical School
Graduated: 1981
Uc San Diego Affil
Graduated: 1982
Graduated: 1984
Scripps Clin Rsch Fdn
Graduated: 1987
Rutgers Medical School
Graduated: 1981
Uc San Diego Affil
Graduated: 1982
Graduated: 1984
Scripps Clin Rsch Fdn
Graduated: 1987
Gregg Joshua Silverman, La Jolla CA
Specialties:
Internal Medicine, Rheumatology, General Practice, Orthopaedic Surgery, Foot and Ankle Orthopaedics
Work:
University of California at San Diego
9500 Gilman Dr, La Jolla, CA 92093
9500 Gilman Dr, La Jolla, CA 92093
Education:
UMDNJ Robert Wood Johnson (1981)
Method For Inhibition Of Phospholamban Activity For The Treatment Of Cardiac Disease And Heart Failure
US Patent:
2009014, Jun 11, 2009
Filed:
Oct 23, 2008
Appl. No.:
12/257329
Inventors:
KENNETH CHIEN - LA JOLLA CA, US
WOLFGANG DILLMAN - LA JOLLA CA, US
SUSUMU MINAMISAWA - LA JOLLA CA, US
HUAPING HE - LA JOLLA CA, US
MASAHIKO HOSHIJIMA - LA JOLLA CA, US
MARKUS MEYER - LA JOLLA CA, US
CHRISTOPHER SCOTT - SAN DIEGO CA, US
YIBIN WANG - LA JOLLA CA, US
GREGG J. SILVERMAN - LA JOLLA CA, US
WOLFGANG DILLMAN - LA JOLLA CA, US
SUSUMU MINAMISAWA - LA JOLLA CA, US
HUAPING HE - LA JOLLA CA, US
MASAHIKO HOSHIJIMA - LA JOLLA CA, US
MARKUS MEYER - LA JOLLA CA, US
CHRISTOPHER SCOTT - SAN DIEGO CA, US
YIBIN WANG - LA JOLLA CA, US
GREGG J. SILVERMAN - LA JOLLA CA, US
International Classification:
A61K 31/7088, A61P 9/00
US Classification:
514 44
Abstract:
The present invention provides a method for the treatment of heart failure through the use of small peptide complexes and recombinant proteins which function to enhance contractility in failing hearts and reduce blood pressure in individuals with hypertension by inhibiting the interaction between phospholamban and sacroplasmic reticulum Ca ATPase (SERCA2a) within cardiomyocytes. In addition, a means is provided for the transport of such therapeutic agents into the cytoplasm and nucleus of cardiomyocytes.
Method For Inhibition Of Phospholamban Activity For The Treatment Of Cardiac Disease And Heart Failure
US Patent:
2004012, Jun 24, 2004
Filed:
Nov 10, 2003
Appl. No.:
10/705791
Inventors:
Kenneth Chien - La Jolla CA, US
Wolfgang Dillman - La Jolla CA, US
Susumu Minamisawa - La Jolla CA, US
Huaping He - La Jolla CA, US
Masahiko Hoshijima - La Jolla CA, US
Markus Meyer - La Jolla CA, US
Christopher Scott - San Diego CA, US
Yibin Wang - La Jolla CA, US
Gregg Silverman - La Jolla CA, US
Wolfgang Dillman - La Jolla CA, US
Susumu Minamisawa - La Jolla CA, US
Huaping He - La Jolla CA, US
Masahiko Hoshijima - La Jolla CA, US
Markus Meyer - La Jolla CA, US
Christopher Scott - San Diego CA, US
Yibin Wang - La Jolla CA, US
Gregg Silverman - La Jolla CA, US
International Classification:
A61K038/17, A61K048/00, A61K039/395
US Classification:
514/007000, 514/044000, 424/130100
Abstract:
The present invention provides a method for the treatment of heart failure through the use of small peptide complexes and recombinant proteins which function to enhance contractility in failing hearts and reduce blood pressure in individuals with hypertension by inhibiting the interaction between phospholamban and sarcoplasmic reticulum Ca ATPase (SERCA2a) within cardiomyocytes. In addition, a means is provided for the transport of such therapeutic agents into the cytoplasm and nucleus of cardiomyocytes.